What can go wrong with the river — and which failure counts in minutes?
Blood conditions organize by what fails: the red fleet (anemia — the world's most common nutritional and chronic-disease outcome, our anemia page's full territory), the balance between clotting and bleeding (DVT/PE on one side — the clot that kills; hemophilia, ITP, and von Willebrand on the other — the bleed that won't stop), the iron economy's failure in both directions (deficiency on one end; hereditary hemochromatosis — the silent overload — on the other, in the same population most likely to buy an iron supplement), and the blood cancers (leukemia, lymphoma, myeloma — the red-flag family, living through the most transformative decade in their treatment history). And the field's emergency tier is among medicine's most time-critical: sepsis, hemorrhage, and clot kill in minutes to hours — the rules that outrank every chapter below.
The common outcome: iron deficiency (the microcytic picture — the world's #1 nutritional deficiency, menstruating and plant-based eaters most at risk), B12/folate deficiency (the macrocytic picture — marrow DNA stalled, nerves at risk), anemia of chronic disease (hepcidin's iron lockdown), and the kidney-EPO failure. A lab-diagnosed family with a treatment for each member. Our anemia page is the full story.
The silent overload: a common Northern-European gene variant (C282Y) that loads iron unchecked for decades — fatigue and joint pain first, then liver, heart, and pancreas damage. The beautiful irony: the treatment is phlebotomy — draining blood, medicine's oldest intervention, to save the modern organ. Screenable with ferritin + transferrin saturation; early treatment prevents everything.
The over-clotting failure: Virchow's triad (stasis, injury, hypercoagulability) turning the repair crew against the river — surgery, long flights, immobility, estrogen, cancer, and inherited factors feeding it. Anticoagulation is a carefully managed prescription tier (warfarin's vitamin-K consistency, the DOACs' fewer checks); the clot that reaches the lungs is the 911 endpoint.
The under-clotting family: hemophilia (the factor-VIII/IX genetics, transformed by factor replacement and gene therapy), von Willebrand disease (the most common inherited bleeding disorder, milder, under-diagnosed), and ITP (the immune attack on platelets). Unexplained bruising and bleeding are the workup triggers — hematology's territory, with a genuinely modern treatment tier.
Leukemia, lymphoma, and myeloma — the marrow's and lymph system's malignant families, announcing themselves in night sweats, weight loss, nodes, and abnormal counts. Living through the most transformative treatment decade in oncology: targeted inhibitors, immunotherapy, and CAR-T cells engineered from the patient's own blood. The red-flag family where referral speed matters.
The point-mutation disease: one amino acid reshaping hemoglobin so it polymerizes under low oxygen — sickling cells that clog vessels and cause the vaso-occlusive pain crisis. The molecular-disease concept's founding example (1949); and since 2023, the first CRISPR-based cure ever approved (Casgevy) — a monogenic disease becoming a fixed one, live in this decade.
Blood prevention is lab literacy, donation arithmetic, and four pattern-recognition rules: